SiBone (NASDAQ:SIBN – Get Free Report) and OrthoPediatrics (NASDAQ:KIDS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.
Profitability
This table compares SiBone and OrthoPediatrics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SiBone | -6.20% | -7.57% | -5.55% |
| OrthoPediatrics | -12.83% | -8.10% | -5.46% |
Earnings and Valuation
This table compares SiBone and OrthoPediatrics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SiBone | $200.93 million | 5.26 | -$18.90 million | ($0.31) | -75.61 |
| OrthoPediatrics | $236.35 million | 3.57 | -$39.65 million | ($1.43) | -22.62 |
SiBone has higher earnings, but lower revenue than OrthoPediatrics. SiBone is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
98.1% of SiBone shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 4.0% of SiBone shares are held by company insiders. Comparatively, 32.5% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
SiBone has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for SiBone and OrthoPediatrics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SiBone | 1 | 0 | 7 | 0 | 2.75 |
| OrthoPediatrics | 1 | 1 | 7 | 0 | 2.67 |
SiBone presently has a consensus price target of $25.00, suggesting a potential upside of 6.66%. OrthoPediatrics has a consensus price target of $30.75, suggesting a potential downside of 4.95%. Given SiBone’s stronger consensus rating and higher probable upside, analysts plainly believe SiBone is more favorable than OrthoPediatrics.
Summary
SiBone beats OrthoPediatrics on 8 of the 12 factors compared between the two stocks.
About SiBone
SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.
About OrthoPediatrics
OrthoPediatrics Corp. develops and markets orthopedic implants and instruments designed specifically for children and adolescents. Its products support surgeons treating a range of pediatric conditions, including fractures, spinal deformities, limb-length differences and other orthopedic disorders. The company’s portfolio includes systems for trauma and deformity correction, scoliosis treatment, limb lengthening and external fixation, as well as specialized surgical instruments. It also provides related education and support for pediatric orthopedic surgeons and care teams.
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
